目的 探討阿托伐他汀聯(lián)合貝那普利對慢性心力衰竭患者的療效及對心功能的影響。方法 選取延安市人民醫(yī)院2014年1月—2017年6月收治的慢性心力衰竭患者110例，按治療方法分成對照組55例、觀察組55例。對照組在常規(guī)治療的基礎上使用貝那普利治療，10 mg/次，1次/d。觀察組在對照組基礎上聯(lián)合阿托伐他汀治療，20 mg/次，1次/d，在晚餐后口服。兩組療程均為6個月。比較兩組臨床療效、心功能相關(guān)指標的變化及不良反應的發(fā)生情況。結(jié)果 觀察組臨床療效的總有效率為89.09%（49/55），顯著高于對照組的72.73%（40/55），差異有統(tǒng)計學意義（P<0.05）。治療前兩組的左室射血分數(shù)（LVEF）、左心室舒張末期內(nèi)徑（LVEDD）、左心室收縮末期內(nèi)徑（LVESD）間無顯著差異。治療后兩組LVEF均顯著降低（P<0.05），對照組LVEDD、LVESD的變化不顯著，而觀察組的顯著降低（P<0.05），且兩組間以上指標比較差異顯著（P<0.05）。對照組不良反應的發(fā)生率是9.09%，觀察組是5.45%，兩組間無顯著差異。結(jié)論 阿托伐他汀聯(lián)合貝那普利對于慢性心力衰竭的療效確切，安全可靠，值得臨床應用推廣。

Objective To explore the clinical efficacy and effects of atorvastatin combined with benazepril on cardiac function in patients with chronic heart failure. Methods Selected 110 patients with chronic heart failure in our hospital from January 2014 to June 2017. All patients were divided into control group and observation group by treatment methods, each of group of 55 cases. The control group was treated with benazepril on the basis of routine treatment. The observation group was treated with atorvastatin on the basis of the control group. The clinical curative effect, changes of cardiac function related indicators and incidence of adverse reactions were compared between the two groups. Results The total effective rate of observation group was 89.09% (49/55), which was significantly higher than that of control group (72.73%, 40/55) (P < 0.05). Before treatment, there was no significant difference between LVEF, LVEDD and LVESD of two groups. After treatment, LVEF in both groups were significantly decreased (P < 0.05), but LVEDD and LVESD in control group were not significantly different, while those in observation group were significantly lower (P < 0.05). The incidence of adverse reactions was 9.09% in the control group and 5.45% in the observation group, with no significant difference between the two groups. Conclusions Atorvastatin combined with benazepril for the treatment of chronic heart failure is accurate, safe and reliable, it is worth promoting the clinical application.